Aytu BioPharma, Inc. (AYTU)

Market Cap	21.41M
Revenue (ttm)	81.66M
Net Income (ttm)	1.64M
Shares Out	8.98M
EPS (ttm)	-0.83
PE Ratio	13.06
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	172,485
Open	2.310
Previous Close	2.290
Day's Range	2.270 - 2.450
52-Week Range	0.950 - 2.960
Beta	0.13
Analysts	Strong Buy
Price Target	10.00 (+319.29%)
Earnings Date	May 14, 2025

About AYTU

Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age and above, and Cotempla XR-ODT extended-release orally disintegrating tablets for patients from six to seventeen years old. It also provides pediatric prescription product portfolio comprising Kar...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• CEO: Joshua Disbrow
• Employees: 102
• Stock Exchange: NASDAQ
• Ticker Symbol: AYTU
• Website: https://aytubio.com

Financial Performance

In 2024, Aytu BioPharma's revenue was $81.00 million, a decrease of -24.58% compared to the previous year's $107.40 million. Losses were -$15.84 million, -7.08% less than in 2023.

Analyst Summary

According to 2 analysts, the average rating for AYTU stock is "Strong Buy." The 12-month stock price target is $10.0, which is an increase of 319.29% from the latest price.

Price Target

$10.0

(319.29% upside)

Analyst Consensus: Strong Buy